Quick summary: The federal childhood immunization schedule has undergone significant changes following an executive order signed in August 2026. Pharmacy professionals play a critical role in staying informed about these updates, identifying vaccination gaps, counseling patients, and improving coverage rates across all age groups.
The immunization schedule has changed considerably over the past 30 years. In 1995, the first harmonized childhood schedule covered just nine diseases. By 2025, it protected against up to 16 infectious agents for children and adolescents alone, and the adult schedule had grown just as significantly.
2026 brought changes of a different kind. On August 10, 2026, the president signed an executive order revamping the federal government’s recommended childhood vaccine schedule, introducing new categories of vaccination recommendations and directing several federal agencies to review how vaccines are approved, administered, and communicated to the public.
This post breaks down what pharmacists need to know about the current immunization landscape, from how vaccines get recommended to the practical implications of recent policy changes.
Related CE course for pharmacists: Immunizations for Pharmacy Professionals: Not a Shot in the Dark – Saving Lives
How does a vaccine get added to the immunization schedule?
Before a vaccine lands on the schedule, it goes through a rigorous review process. The FDA’s Center for Biologics Evaluation and Research(CBER) oversees vaccine approval, requiring clinical trial data demonstrating both safety and efficacy. Manufacturers must submit a biologics license application before any vaccine can be approved for public use.
FDA approval alone doesn’t add a vaccine to the schedule. That’s where the ACIP comes in. The Advisory Committee on Immunization Practices consists of 15 experts appointed by the Secretary of the U.S. Department of Health and Human Services. The ACIP is the only federal entity historically authorized to issue routine vaccination recommendations, covering:
- Age ranges for administration
- Number of doses and dosing intervals
- Contraindications and precautions
Once the ACIP issues a recommendation, the CDC publishes it as part of the annual immunization schedule. Schedules for children and adolescents (ages 0–18) have been published since the mid-1990s. The adult schedule has been published annually since 2002.
The August 2026 executive order introduces a new framework that divides childhood immunizations into three categories: vaccines recommended for all children, vaccines recommended for high-risk groups, and vaccines recommended through shared clinical decision-making. This represents a significant structural change to how recommendations are communicated. Pharmacy professionals should monitor updates from HHS and the CDC as agency guidance evolves over the coming months.
Related CE course for pharmacists: Child, Adolescent, and Adult Immunization Schedules
What are the key vaccines on the child and adolescent immunization schedule?
The 2025–2026 child and adolescent schedule covers up to 16 infectious agents. Full coverage can involve more than three dozen shots, which is why combination vaccines and catch-up scheduling are so important. However, the August 2026 executive order directs HHS to draft recommendations within 90 days on how to administer core childhood vaccines as single vaccines rather than combination products, starting with the MMR vaccine. The order also states that HHS will guarantee continued availability of the combined MMR vaccine during this transition.
Here’s an overview of the most clinically significant vaccines and their current recommendations:
Influenza
Annual vaccination is recommended for all children 6 months through 18 years of age. Children receiving the influenza vaccine for the first time need two doses, at least four weeks apart. The live attenuated influenza vaccine (LAIV) remains an option for children 2 years and older who are otherwise eligible, though it’s contraindicated in immunocompromised patients and those with asthma.
DTaP and Tdap
DTaP is recommended at 2, 4, 6, and 15–18 months, with a booster at 4–6 years. Tdap follows at 11–12 years. Immunity to pertussis declines within 5–10 years after vaccination, which makes the adolescent Tdap dose particularly important. In 2022, the CDC reported 3,044 pertussis cases—a 44% increase from 2021—with adolescents and adults accounting for about 55% of cases (CDC, 2024).
HPV
Gardasil 9 is the only HPV vaccine currently available in the United States. It’s recommended routinely for children 11–12 years of age, with vaccination possible as early as age 9. The CDC estimates that more than 37,800 HPV-attributable cancers occur each year (CDC, 2025). Despite this, only about 58.6% of adolescents were vaccinated as of 2022 (NCI, 2025).
MMR
Under the August 2026 executive order, the MMR vaccine is included in the category of vaccines recommended for all children. The order states that once separate measles, mumps, and rubella vaccine products become available, the combined MMR vaccine should be administered as three separate shots. In the interim, the combined MMR vaccine remains available and recommended.
Pharmacy professionals should be aware that as of mid-2026, confirmed measles cases in the U.S. have reached 2,318—the highest annual count since 1991 (AHA, 2026).
RSV (categorized under shared clinical decision-making, 2026)
Under the new executive order framework, RSV vaccination has been reclassified as a recommendation for certain high-risk groups or through shared clinical decision-making, rather than a universal recommendation. Prior to this change, infants born to mothers who did not receive the RSV vaccine at least 14 days before delivery were recommended to receive one dose of nirsevimab shortly after birth (October through March). Pharmacy professionals should monitor updated HHS guidance on how this reclassification applies in clinical practice.
Meningococcal
MenACWY is recommended at 11–12 years, with a booster at 16. In 2023, a new pentavalent vaccine (MenABCWY) became available for patients 10 years and older who need both MenACWY and MenB at the same visit, administered in two doses at least six months apart.
What are the key vaccines on the adult immunization schedule?
The adult immunization schedule addresses vaccination needs from age 19 through older adulthood. Despite clear recommendations, adult vaccination rates remain well below national goals. According to 2018 National Health Interview Survey data, only 69% of adults 65 and older had received pneumococcal vaccination, and just 47% of adults 50–64 reported receiving influenza vaccination in the past year (Lu et al., 2021).
Key highlights:
RSV for adults
Under the 2025 schedule, one dose of RSV vaccine was recommended for all adults 75 and older, with shared clinical decision-making for adults 60–74. Pharmacy professionals should monitor for any updates to adult RSV recommendations as HHS guidance develops in response to the 2026 executive order.
Herpes zoster (RZV)
The recombinant zoster vaccine (RZV) is recommended for all adults 50 and older. RZV demonstrated 97.2% efficacy in reducing herpes zoster incidence in clinical trials, with an overall efficacy of 91.2% against postherpetic neuralgia (Harbecke et al., 2021). Notably, RZV is also recommended for immunocompromised adults 19 and older.
Pneumococcal
Adults 50 and older who haven’t previously received a pneumococcal vaccine should receive one dose of PCV20 or PCV21, or one dose of PCV15 followed by PPSV23. This recommendation applies regardless of prior vaccination history with PCV7.
COVID-19
One or more doses of an updated COVID-19 vaccine are recommended for all adults, with additional doses recommended for immunocompromised individuals.
What contraindications should pharmacy professionals know?
Contraindication awareness is essential for safe vaccine administration. Here are the key principles to keep in mind:
General contraindications for all vaccines:
- Serious allergic reaction to a prior dose
- Severe allergy to any vaccine component
Situations that are NOT contraindications (per CDC, 2025):
- Mild illness with or without low-grade fever
- Current antimicrobial therapy (with exceptions for certain antivirals)
- Premature birth (except HepB in specific circumstances)
- History of Guillain-Barré syndrome (GBS) — use caution with specific vaccines, but not an automatic contraindication
Live vaccines to avoid in pregnancy: MMR, VAR, and LAIV are all contraindicated. The zoster vaccine should also be delayed.
Immunocompromised patients: Avoid live vaccines (MMR, VAR, LAIV) in most immunocompromised individuals. RZV is an exception and is recommended for immunocompromised adults 19 and older.
For allergy-related contraindications, review the patient’s history carefully. Yeast allergy is a contraindication for HPV and HepB vaccines. Neomycin allergy contraindicates IPV, MMR, VAR, HepA, and some influenza vaccines. Always check the package insert for specific guidance.
How can pharmacy professionals address common vaccine safety concerns?
Patients and caregivers often come in with safety questions. You’ll be better prepared to answer them if you know the evidence.
MMR and autism: Multiple large studies have found no link. A 2019 Danish cohort study of 657,461 children found no increased autism risk in MMR recipients, including in high-risk subgroups (Hviid et al., 2019). The Institute of Medicine concluded in 2004 that the evidence “favors rejection of a causal relationship.”
Thimerosal and autism: No association has been found, and most childhood vaccines are now thimerosal-free or contain only trace amounts.
Multiple vaccines at once: No evidence supports the idea that receiving multiple vaccines at a single visit weakens the immune system. In fact, despite more vaccines being given today, the overall immunologic load has decreased thanks to advances in vaccine technology (Gerber & Offit, 2009). Note that the August 2026 executive order recommends administering immunizations at separate medical visits when feasible. Pharmacy professionals should be prepared to counsel patients on how this recommendation may affect scheduling.
Rotavirus and intussusception: The risk exists but is small—approximately 1 in 20,000 to 1 in 100,000 doses (CDC). This risk is weighed against the substantial burden of rotavirus disease, which previously caused up to 60 deaths, 70,000 hospitalizations, and $1 billion in costs annually in the pre-vaccine era.
How can pharmacy professionals reduce missed vaccination opportunities?
Vaccination gaps in both pediatric and adult populations are well documented. Racial and ethnic disparities make the problem more pronounced. Black adults are vaccinated at rates averaging 18% lower than White adults across multiple vaccines (Lu et al., 2021).
Here’s what the evidence supports for improving coverage:
- Standing orders: Evidence shows they consistently improve adult vaccination coverage across practice settings.
- Reminder and recall systems: Mailed reminders, phone calls, and electronic messages increase coverage in both children and adults.
- Physician/provider reminders: Chart notations and patient lists improve coverage.
- Combination vaccines: The ACIP has recommended combination vaccines whenever possible to reduce the number of injections and improve coverage. Note that the 2026 executive order is directing HHS to develop alternative single-vaccine options, though no changes to product availability have been implemented at the time of publication.
- Assess at every visit: Every healthcare encounter is an opportunity. Check vaccination status at new patient visits, annual wellness visits, and flu shot appointments.
For pediatric patients, the Vaccines for Children (VFC) program covers all ACIP-recommended vaccines for eligible children through age 18, including those on Medicaid, uninsured children, underinsured children, and American Indian or Alaska Native children.
Put your immunization knowledge to work
Keeping up with schedule changes takes commitment, and in the current environment, that commitment matters more than ever. The Immunization Action Coalition (immunize.org) is a reliable resource for staying current as federal guidance continues to evolve.
As a pharmacy professional, your expertise matters. Every time you check a vaccination history, answer a hesitant patient’s question, or administer an overdue vaccine, you’re contributing to better public health outcomes. That’s worth the effort to stay informed.
Ready to go deeper? Complete continuing education pharmacy courses on the current immunization schedule to earn CE credit and strengthen your clinical practice.
Frequently asked questions about the immunization schedule
How often does the immunization schedule change?
The CDC publishes updated immunization schedules for children, adolescents, and adults annually, usually at the start of the calendar year. The ACIP also issues mid-year updates when new vaccines are approved or recommendations change. As of August 2026, an executive order has introduced a new framework for childhood vaccine categories. Pharmacy professionals should monitor both the MMWR and the CDC website for schedule updates throughout the year.
Can patients receive multiple vaccines at the same visit?
The CDC and ACIP have supported co-administration of vaccines whenever possible to prevent coverage gaps. The August 2026 executive order recommends administering vaccines at separate visits when feasible. Pharmacy professionals should stay informed as HHS develops specific guidance on how this recommendation will be implemented in practice.
What should pharmacy professionals do when a patient is behind on vaccines?
Use the CDC’s catch-up immunization schedule, which provides minimum age requirements and dosing intervals for patients who have missed or delayed doses. The catch-up schedule is published annually alongside the routine immunization schedules.
Are there vaccines contraindicated during pregnancy?
Yes. MMR, VAR (varicella), and LAIV are contraindicated in pregnancy. The zoster vaccine should also be delayed. In contrast, Tdap is recommended during every pregnancy (ideally in the second or third trimester), and the RSV vaccine (Abrysvo) was recommended at 32–36 weeks’ gestation during RSV season under the 2025 schedule. Monitor for updates to RSV recommendations as federal guidance is revised.
Where should pharmacy professionals report adverse vaccine events?
Adverse events should be reported to the Vaccine Adverse Event Reporting System (VAERS) at vaers.hhs.gov. VAERS accepts voluntary reports from healthcare providers, vaccine manufacturers, and the public. For certain events, reporting may also be required by state or federal law.
